학술논문
Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease.
Document Type
Academic Journal
Author
Merle M; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Fischbacher D; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Liepert A; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Grabrucker C; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Kroell T; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Kremser A; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Dreyssig J; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Freudenreich M; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Schuster F; Department for Pediatric Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany.; Borkhardt A; Department for Pediatric Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany.; Kraemer D; Department for Hematology, Municipal Hospital Oldenburg, Oldenburg, Germany.; Koehne CH; Department for Hematology, Municipal Hospital Oldenburg, Oldenburg, Germany.; Kolb HJ; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Helmholtz Center, Clinical Cooperative Group Human Cell Transplantation (CCG-HCT), Munich, Germany.; Schmid C; Department for Hematology, University Hospital Augsburg, Augsburg, Germany.; Schmetzer HM; Department for Hematopoietic Transplantations, Med III, University Hospital of Munich, Munich, Germany.; Helmholtz Center, Clinical Cooperative Group Human Cell Transplantation (CCG-HCT), Munich, Germany.
Source
Publisher: Informa Healthcare Country of Publication: England NLM ID: 8504629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4311 (Electronic) Linking ISSN: 08820139 NLM ISO Abbreviation: Immunol Invest Subsets: MEDLINE
Subject
Language
English
Abstract
In cancer or hematologic disorders, chemokines act as growth- or survival factors, regulating hematopoiesis and angiogenesis, determining metastatic spread and controlling leukocyte infiltration into tumors to inhibit antitumor immune responses. The aim was to quantify the release of CXCL8, -9, -10, CCL2, -5, and IL-12 in AML/MDS-pts' serum by cytometric bead array and to correlate data with clinical subtypes and courses. Minimal differences in serum-levels subdivided into various groups (e.g. age groups, FAB-types, blast-proportions, cytogenetic-risk-groups) were seen, but higher release of CXCL8, -9, -10 and lower release of CCL2 and -5 tendentially correlated with more favorable subtypes (<50 years of age, <80% blasts in PB). Comparing different stages of the disease higher CCL5-release in persisting disease and a significantly higher CCL2-release at relapse were found compared to first diagnosis - pointing to a change of 'disease activity' on a chemokine level. Correlations with later on achieved response to immunotherapy and occurrence of GVHD were seen: Higher values of CXCL8, -9, -10 and CCL2 and lower CCL5-values correlated with achieved response to immunotherapy. Predictive cut-off-values were evaluated separating the groups in 'responders' and 'non-responders'. Higher levels of CCL2 and -5 but lower levels of CXCL8, -9, -10 correlated with occurrence of GVHD. We conclude, that in AML-pts' serum higher values of CXCL8, -9, -10 and lower values of CCL5 and in part of CCL2 correlate with more favorable subtypes and improved antitumor'-reactive function. This knowledge can contribute to develop immune-modifying strategies that promote antileukemic adaptive immune responses.